Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease

Cold Spring Harbor Perspectives in Medicine

Volumn 2, Issue 6, 2012, Pages

  Masters, Colin L ^a   Selkoe, Dennis J ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b Brigham and Women's Hospital Center for Neurologic Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINESTERASE; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA SYNUCLEIN; AMPA RECEPTOR; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN [1-40]; AMYLOID PRECURSOR PROTEIN; CHAPERONE; CHOLINERGIC RECEPTOR; COPPER; IRON; LIPOPROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN; METAL ION; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SYNTHETIC PEPTIDE; TAU PROTEIN; UNCLASSIFIED DRUG; ZINC; AMYLOID;

ALZHEIMER DISEASE; AMINO ACID COMPOSITION; AMINO TERMINAL SEQUENCE; AMYLOID PLAQUE; BRAIN HOMOGENATE; CLINICAL TRIAL (TOPIC); CONFOCAL MICROSCOPY; CRYOELECTRON MICROSCOPY; FOURIER TRANSFORM MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; LONG TERM DEPRESSION; LONG TERM POTENTIATION; NONHUMAN; OLIGOMERIZATION; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; REVIEW; SENILE PLAQUE; WESTERN BLOTTING; METABOLISM;

MAMMALIA; PRIMATES;

ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PEPTIDES; HUMANS; PLAQUE, AMYLOID;

EID: 84879829589     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a006262     Document Type: Review

References (226)

1. 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52: 487-501.
2. 1-42oligomers to fibrils. Nat Struct Mol Biol 17: 561-567.
3. Allsop D, Landon M, Kidd M. 1983. The isolation and amino acid composition of senile plaque core protein. Brain Res 259: 348-352.
4. Bales KR, Liu F, Wu S, Lin SZ, Koger D, DeLong C, Hansen JC, Sullivan PM, PaulSM. 2009. Human APOE isoform-dependent effects on brain β-amyloid levels in PDAPP transgenic mice. J Neurosci 29: 6771-6779.
5. 3+)-amyloid beta (Aβ) peptide complexes: A computational study. J Comput Chem 30: 1405-1413.
6. 40, either soluble or aggregated, is a remarkably potent antioxidant in cell-free oxidative systems. Biochemistry 48: 4354-4370.
7. Bateman DA, Chakrabartty A. 2009. Two distinct conformations of Aβ aggregates on the surface of living PC12 cells. Biophys J 96: 4260-4267.
8. Behbehani GR, Mirzaie M. 2009. A high performance method for thermodynamic study on the binding of copper ion and glycine with Alzheimer's amyloid β peptide. J Therm Anal Calorim 96: 631-635.
9. Bernstein SL, Dupuis NF, Lazo ND, Wyttenbach T, Condron MM, Bitan G, Teplow DB, Shea J-E, Ruotolo BT, Robinson CV, et al. 2009. Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nat Chem 1: 326-331.
10. Blennow K, Zetterberg H, Fagan AM. 2011. Fluid biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006221.
11. Brorsson AC, Bolognesi B, Tartaglia GG, Shammas SL, Favrin G, Watson I, Lomas DA, Chiti F, Vendruscolo M, Dobson CM, et al. 2010. Intrinsic determinants of neurotoxic aggregate formation by the amyloid β peptide. Biophys J 98: 1677-1684.
12. Brzyska M, Trzesniewska K, Wieckowska A, Szczepankiewicz A, Elbaum D. 2009. Electrochemical and conformational consequences of copper (Cu-I and Cu-II) binding to β-amyloid(1-40). Chembiochem 10: 1045-1055.
13. Butterfield DA, Galvan V, Lange MB, Tang H, Sowell RA, Spilman P, FombonneJ, Gorostiza O, Zhang J, Sultana R, et al. 2010. In vivo oxidative stress in brain of Alzheimer disease transgenic mice: Requirement for methionine 35 in amyloid β-peptide of APP. Free Radic Biol Med 48: 136-144.
14. Caspar DL. 2009. Inconvenient facts about pathological amyloid fibrils. Proc Natl Acad Sci 106: 20555-20556.
15. Castano EM, Ghiso J, Prelli F, Gorevic PD, Migheli A, Frangione B. 1986. In vitroformation of amyloid fibrils from two synthetic peptides of different lengths homologous to Alzheimer's disease β-protein. Biochem Biophys Res Commun 141: 782-789.
16. Chebaro Y, Mousseau N, Derreumaux P. 2009. Structures and thermodynamics of Alzheimer's amyloid-β Aβ(16-35) monomer and dimer by replica exchange molecular dynamics simulations: Implication for full-length Aβ fibrillation. J Phys Chem B 113: 7668-7675.
17. Chi EY, Frey SL, Winans A, Lam KLH, Kjaer K, Majewski J, Lee KYC. 2010. Amyloid-β fibrillogenesis seeded by interface-induced peptide misfolding and self-assembly. Biophys J 98: 2299-2308.
18. Ciccotosto GD, Tew DJ, Drew SC, Smith DG, Johanssen T, Lal V, Lau TL, PerezK, Curtain CC, Wade JD, et al. 2011. Stereospecific interactions are necessary for Alzheimer disease amyloid-β toxicity. Neurobiol Aging 32: 235-248.
19. Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. 2005. Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron 48: 913-922.
20. Cirrito JR, Kang JE, Lee J, Stewart FR, Verges DK, Silverio LM, Bu G, Mennerick S, Holtzman DM. 2008. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. Neuron 58: 42-51.
21. Cizas P, Budvytyte R, Morkuniene R, Moldovan R, Broccio M, Losche M, NiauraG, Valincius G, Borutaite V. 2010. Size-dependent neurotoxicity of β-amyloid oligomers. Arch Biochem Biophy 496: 84-92.
22. Crouch PJ, Hung LW, Adlard PA, Cortes M, Lal V, Filiz G, Perez KA, Nurjono M, Caragounis A, Du T, et al. 2009a. Increasing Cu bioavailability inhibits Aβ oligomers and tau phosphorylation. Proc Natl Acad Sci 106: 381-386.
23. Crouch PJ, Tew DJ, Du T, Nguyen DN, Caragounis A, Filiz G, Blake RE, TrounceIA, Soon CPW, Laughton K, et al. 2009b. Restored degradation of the Alzheimer's amyloid-β peptide by targeting amyloid formation. J Neurochem 108: 1198-1207.
24. D'Arrigo C, Tabaton M, Perico A. 2009. N-terminal truncated pyroglutamyl β amyloid peptide Aβpy3-42 shows a faster aggregation kinetics than the full-length Aβ1-42. Biopolymers 91: 861-873.
25. da Silva GFZ, Lykourinou V, Angerhofer A, L-J Ming. 2009. Methionine does not reduce Cu(II)-β-amyloid!-Rectification of the roles of methionine-35 and reducing agents in metal-centered oxidation chemistry of Cu(II)-β-amyloid. Biochim Biophy Acta 1792: 49-55.
26. Damante CA, Osz K, Nagy Z, Pappalardo G, Grasso G, Impellizzeri G, RizzarelliE, Sovago I. 2009. Metal loading capacity of Aβ N-terminus: a combined potentiometric and spectroscopic study of zinc(II) complexes with Aβ(1-16), its short or mutated peptide fragments and its polyethylene glycol-ylated analogue. Inorg Chem 48: 10405-10415.
27. Davis CH, Berkowitz ML. 2009a. Interaction between amyloid-β (1-42) peptide and phospholipid bilayers: A molecular dynamics study. Biophys J 96: 785-797.
28. Davis CH, Berkowitz ML. 2009b. Structure of the amyloid-β (1-42) monomer absorbed to model phospholipid bilayers: A molecular dynamics study. J Phys Chem B 113: 14480-14486.
29. Davis TJ, Soto-Ortega DD, Kotarek JA, Gonzalez-Velasquez FJ, Sivakumar K, Wu LY, Wang Q, Moss MA. 2009. Comparative study of inhibition at multiple stages of amyloid-β self-assembly provides mechanistic insight. Mol Pharmacol 76: 405-413.
30. De Ferrari GV, Canales MA, Shin I, Weiner LM, Silman I, Inestrosa NC. 2001. A structural motif of acetylcholinesterase that promotes amyloid β-peptide fibril formation. Biochemistry 40: 10447-10457.
31. Deshpande A, Kawai H, Metherate R, Glabe CG, Busciglio J. 2009. A role for synaptic zinc in activity-dependent Aβ oligomer formation and accumulation at excitatory synapses. J Neurosci 29: 4004-4015.
32. Di Carlo M. 2010. Beta amyloid peptide: From different aggregation forms to the activation of different biochemical pathways. Eur Biophys J Biophys Lett 39: 877-888.
33. Dickens MG, Franz KJ. 2010. A prochelator activated by hydrogen peroxide prevents metal-induced amyloid β aggregation. Chembiochem 11: 59-62.
34. Ding H, Wong PT, Lee EL, Gafni A, Steel DG. 2009. Determination of the oligomer size of amyloidogenic protein β-amyloid(1-40) by single-molecule spectroscopy. Biophys J 97: 912-921.
35. Dorlet P, Gambarelli S, Faller P, Hureau C. 2009. Pulse EPR spectroscopy reveals the coordination sphere of copper(II) ions in the 1-16 amyloid-β peptide: A key role of the first two N-terminus residues. Angew Chem Int Ed Engl 48: 9273-9276.
36. 2+ coordination of Alzheimer's disease amyloid-β peptide-relevance to N-terminally truncated forms. J Am Chem Soc 131: 8760-8761.
37. Drew SC, Noble CJ, Masters CL, Hanson GR, Barnham KJ. 2009b. Pleomorphic copper coordination by Alzheimer's disease amyloid-β peptide. J Am Chem Soc 131: 1195-1207.
38. Drochioiu G, Manea M, Dragusanu M, Murariu M, Dragan ES, Petre BA, Mezo G, Przybylski M. 2009. Interaction of β-amyloid (1-40) peptide with pairs of metal ions: An electrospray ion trap mass spectrometric model study. Biophys Chem 144: 9-20.
39. Duce JA, Tsatsanis A, Cater MA, James SA, Robb E, Wikhe K, Leong SL, Perez K, Johanssen T, Greenough MA, et al. 2010. Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell 142: 857-867.
40. Edwin NJ, Hammer RP, McCarley RL, Russo PS. 2010. Reversibility of β-amyloid self-assembly: Effects of pH and added salts assessed by fluorescence photobleaching recovery. Biomacromolecules 11: 341-347.
41. Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan ZX, Roth K, Aguzzi A, Staufenbiel M, Walker LC, et al. 2009. Induction of cerebral β-amyloidosis: Intracerebral versus systemic Aβ inoculation. Proc Natl Acad Sci 106: 12926-12931.
42. Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M. 2010. Peripherally applied Aβ-containing inoculates induce cerebral β-amyloidosis. Science 330: 980-982.
43. Englund H, Degerman Gunnarsson M, Brundin RM, Hedlund M, Kilander L, Lannfelt L, Pettersson FE. 2009. Oligomerization partially explains the lowering of Aβ42 in Alzheimer's disease cerebrospinal fluid. Neurodegener Dis 6: 139-147.
44. Faller P. 2009. Copper and zinc binding to amyloid-β: Coordination, dynamics, aggregation, reactivity and metal-ion transfer. Chembiochem 10: 2837-2845.
45. Feng Y, Wang XP, Yang SG, Wang YJ, Zhang X, Du XT, Sun XX, Zhao M, Huang L, Liu RT. 2009. Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology 30: 986-995.
46. Finder VH, Vodopivec I, Nitsch RM, Glockshuber R. 2010. The recombinant amyloid-β peptide Aβ1-42 aggregates faster and is more neurotoxic than synthetic Aβ1-42. J Mol Biol 396: 9-18.
47. Friede RL. 1965. Enzyme histochemical studies of senile plaques. J Neuropathol Exp Neurol 24: 477-491.
48. Friedman R, Pellarin R, Caflisch A. 2009. Amyloid aggregation on lipid bilayers and its impact on membrane permeability. J Mol Biol 387: 407-415.
49. Fu ZM, Luo Y, Derreumaux P, Wei GH. 2009. Induced β-barrel formation of the Alzheimer's Aβ 25-35 oligomers on carbon nanotube surfaces: Implication for amyloid fibril inhibition. Biophys J 97: 1795-1803.
50. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, Allsop D, Nakagawa M. 2010. High-molecular-weight β-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24: 2716-2726.
51. Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, CarrT, Clemens J, Donaldson T, Gillespie F, et al. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373: 523-527.
52. Gardberg A, Dice L, Pridgen K, Ko J, Patterson P, Ou S, Wetzel R, Dealwis C. 2009. Structures of Aβ-related peptide-monoclonal antibody complexes. Biochemistry 48: 5210-5217.
53. Glenner GG. 1979. Congophilic microangiopathy in the pathogenesis of Alzheimer's syndrome (presenile dementia). Med Hypotheses 5: 1231-1236.
54. Glenner GG, Wong CW. 1984a. Alzheimer's disease and Down's syndrome: Sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122: 1131-1135.
55. Glenner GG, Wong CW. 1984b. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890.
56. Gorevic P, Goni F, Pons-Estel B, Alvarez F, Peress R, Frangione B. 1986. Isolation and partial characterization of neurofibrillary tangles and amyloid plaque cores in Alzheimer's disease: Immunohistological studies. J Neuropathol Exp Neurol 45: 647-664.
57. Grimaldi M, Scrima M, Esposito C, Vitiello G, Ramunno A, Limongelli V, D'Errico G, Novellino E, D'Ursi AM. 2010. Membrane charge dependent states of the β-amyloid fragment Aβ (16-35) with differently charged micelle aggregates. Biochim Biophys Acta 1798: 660-671.
58. Haass C, Selkoe DJ. 2007. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 8: 101-112.
59. Haass C, Kaether C, Sisodia S, Thinakaran G. 2011. Trafficking and proteolytic processing of APP. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006270.
60. Haeffner F, Barnham KJ, Bush AI, Brinck T. 2010. Generation of soluble oligomeric β-amyloid species via copper catalyzed oxidation with implications for Alzheimer's disease: A DFT study. J Mol Model 16: 1103-1108.
61. Hamaguchi T, Ono K, Murase A, Yamada M. 2009. Phenolic compounds prevent Alzheimer's pathology through different effects on the amyloid-β aggregation pathway. Am J Pathol 175: 2557-2565.
62. Hamley IW, Nutt DR, Brown GD, Miravet JF, Escuder B, Rodriguez-Llansola F. 2010. Influence of the solvent on the self-assembly of a modified amyloid beta peptide fragment. II. NMR and computer simulation investigation. J Phys Chem B114: 940-951.
63. Harper JD, Wong SS, Lieber CM., Lansbury PT Jr. 1997. Observation of metastable Aβ amyloid protofibrils by atomic force microscopy. Chem Biol 4: 119-125.
64. Hawkes CA, Deng LH, Shaw JE, Nitz M, McLaurin J. 2010. Small molecule β-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease. Eur J Neurosci 31: 203-213.
65. Hellstrand E, Sparr E, Linse S. 2010. Retardation of Aβ fibril formation by phospholipid vesicles depends on membrane phase behavior. Biophys J 98: 2206-2214.
66. Holtzman D, Herz J, Bu Guojun. 2011. Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006312.
67. Horn AH, Sticht H. 2010. Amyloid-β42 oligomer structures from fibrils: A systematic molecular dynamics study. J Phys Chem B 114: 2219-2226.
68. Hsiao K, Chapman P, Nilsen S, Ekman C, Harigaya Y, Younkin S, Yang F, ColeG. 1996. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274: 99-102.
69. Hu NW, Klyubin I, Anwy R, Rowan MJ. 2009. GluN2B subunit-containing NMDA receptor antagonists prevent Aβ-mediated synaptic plasticity disruption in vivo. Proc Natl Acad Sci 106: 20504-20509.
70. Hureau C, Balland V, Coppel Y, Solari PL, Fonda E, Faller P. 2009a. Importance of dynamical processes in the coordination chemistry and redox conversion of copper amyloid-β complexes. J Biol Inorg Chem 14: 995-1000.
71. Hureau C, Coppel Y, Dorlet P, Solari PL, Sayen S, Guillon E, Sabater L, Faller P. 2009b. Deprotonation of the Asp1-Ala2 peptide bond induces modification of the dynamic copper(II) environment in the amyloid-β peptide near physiological pH. Angew Chem Int Ed Engl 48: 9522-9525.
72. Jiang D, Li X, Williams R, Patel S, Men L, Wang Y, Zhou F. 2009a. Ternary complexes of iron, amyloid-β, and nitrilotriacetic acid: Binding affinities, redox properties, and relevance to iron-induced oxidative stress in Alzheimer's disease. Biochemistry 48: 7939-7947.
73. Jiang DL, Dinh KL, Ruthenburg TC, Zhang Y, Su L, Land DP, Zhou FM. 2009b. A kinetic model for β-amyloid adsorption at the air/solution interface and its implication to the β-amyloid aggregation process. J Phys Chem B 113: 3160-3168.
74. Jiang DL, Li XJ, Liu L, Yagnik GB, Zhou FM. 2010. Reaction rates and mechanism of the ascorbic acid oxidation by molecular oxygen facilitated by Cu(II)-containing amyloid-β complexes and aggregates. J Phys Chem B 114: 4896-4903.
75. Jin M, Shepardson N, Yang T, Walsh D, Selkoe D. 2011. Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci 108: 5819-5824.
76. Johnson KA, Fox NC, Sperling RA, Klunk WE. 2011. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006213.
77. Jun S, Gillespie JR, Shin BK, Saxena S. 2009. The second Cu(II)-binding site in a proton-rich environment interferes with the aggregation of amyloid-β(1-40) into amyloid fibrils. Biochemistry 48: 10724-10732.
78. Kaether C, Schmitt S, Willem M, Haass C. 2006. Amyloid precursor protein and Notch intracellular domains are generated after transport of their precursors to the cell surface. Traffic 7: 408-415.
79. Kajava AV, Baxa U, Steven AC. 2010. β arcades: Recurring motifs in naturally occurring and disease-related amyloid fibrils. FASEB J 24: 1311-1319.
80. Kang J, Lemaire H-G, Unterbeck A, Salbaum JM, Masters CL, Grzeschik K-H, Multhaup G, Beyreuther K, Muller-Hill B. 1987. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736.
81. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. 2001. Age-dependent changes in brain, CSF, and plasma amyloid β protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372-381.
82. Kawasaki K, Ogiwara N, Sugano M, Okumura N, Yamauchi K. 2009. Sialic acid moiety of apolipoprotein E and its impact on the formation of lipoprotein particles in human cerebrospinal fluid. Clin Chim Acta 402: 61-66.
83. Kayed R, Pensalfini A, Margol L, Sokolov Y, Sarsoza F, Head E, Hall J, Glabe C. 2009. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem 284: 4230-4237.
84. Kirschner DA, Inouye H, Duffy LK, Sinclair A, Lind M, Selkoe DJ. 1987. Synthetic peptide homologous to β protein from Alzheimer disease forms amyloid-like fibrils in vitro. Proc Natl Acad Sci 84: 6953-6957.
85. Koffie RM, Meyer-Luehmann M, Hashimoto T, Adams KW, Mielke ML, Garcia-Alloza M, Micheva KD, Smith SJ, Kim ML, Lee VM, et al. 2009. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci 106: 4012-4017.
86. Kotarek JA, Moss MA. 2010. Impact of phospholipid bilayer saturation on amyloid-β protein aggregation intermediate growth: A quartz crystal microbalance analysis. Anal Biochem 399: 30-38.
87. Ladiwala AR, Lin JC, Bale SS, Marcelino-Cruz AM, Bhattacharya M, Dordick JS, Tessier PM. 2010. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Aβ into off-pathway conformers. J Biol Chem 285: 24228-24237.
88. LaFerla F, Duff K. 2011. Animal models of Alzheimer disease. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006320.
89. 1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci 95: 6448-6453.
90. Laurén J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. 2009. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers. Nature 457: 1128-1132.
91. Lemkul JA, Bevan DR. 2009. Perturbation of membranes by the amyloid β-peptide-a molecular dynamics study. FEBS J 276: 3060-3075.
92. Lesné S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A, Gallagher M, AsheKH. 2006. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440: 352-357.
93. Lesné S, Sherman MA, Handoka MA, Schneider JA, Bennett DA, Ashe KH. 2009. Distinct brain Aβ oligomers are associated with different stages of Alzheimer's disease. Soc Neurosci (Abstr 62720).
94. Li S, Hong S, Shepardson NE, Walsh DM, Shankar GM, Selkoe D. 2009. Soluble oligomers of amyloid β protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 62: 788-801.
95. Li H, Monien BH, Fradinger EA, Urbanc B, Bitan G. 2010. Biophysical characterization of Aβ42 C-terminal fragments: Inhibitors of Aβ42 neurotoxicity. Biochemistry 49: 1259-1267.
96. Liu L, Zhang L, Mao X, Niu L, Yang Y, Wang C. 2009a. Chaperon-mediated single molecular approach toward modulating Aβ peptide aggregation. Nano Lett 9: 4066-4072.
97. Liu Q, Huang Y, Xue FQ, Simard A, DeChon J, Li G, Zhang JL, Lucero L, Wang M, Sierks M, et al. 2009b. A novel nicotinic acetylcholine receptor subtype in basal gorebrain cholinergic neurons with high sensitivity to amyloid peptides. J Neurosci 29: 918-929.
98. Lui JK, Laws SM, Li QX, Villemagne VL, Ames D, Brown B, Bush AI, De Ruyck K, Dromey J, Ellis KA, et al. 2010a. Plasma amyloid-β as a biomarker in Alzheimer's disease: The AIBL study of aging. J Alzheimers Dis 20: 1233-1242.
99. Liu RQ, Zhou QH, Ji SR, Zhou Q, Feng D, Wu Y, Sui SF. 2010b. Membrane localization of β-amyloid 1-42 in lysosomes: A possible mechanism for lysosome labilization. J Biol Chem 285: 19986-19996.
100. Lulevich V, Zimmer CC, Hong HS, Jin LW, Liu GY. 2010. Single-cell mechanics provides a sensitive and quantitative means for probing amyloid-β peptide and neuronal cell interactions. Proc Natl Acad Sci 107: 13872-13877.
101. Ma XJ, Liu L, Mao XB, Niu L, Deng K, Wu WH, Li YM, Yang YL, Wang C. 2009. Amyloid β (1-42) folding multiplicity and single-molecule binding behavior studied with STM. J Mol Biol 388: 894-901.
102. Mandelkow E-M, Mandelkow E. 2011. Biochemistry and cell biology of Tau protein in neurofibrillary degeneration. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006247.
103. Mao YL, Shang ZG, Imai Y, Hoshino T, Tero R, Tanaka M, Yamamoto N, Yanagisawa K, Urisu T. 2010. Surface-induced phase separation of a sphingomyelin/cholesterol/ganglioside GM1-planar bilayer on mica surfaces and microdomain molecular conformation that accelerates Aβ oligomerization. Biochim Biophys Acta 1798: 1090-1099.
104. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. 1985. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci 82: 4245-4249.
105. Masuda Y, Uemura S, Ohashi R, Nakanishi A, Takegoshi K, Shimizu T, Shirasawa T, Irie K. 2009. Identification of physiological and toxic conformations in Aβ 42 aggregates. Chembiochem 10: 287-295.
106. McDonald JM, Savva GM, Brayne C, Welzel AT, Forster G, Shankar GM, SelkoeDJ, Ince PG, Walsh DM, Medical Research Council Cognitive Function and Aging Study. 2010. The presence of sodium dodecyl sulphate-stable Aβ dimers is strongly associated with Alzheimer-type dementia. Brain 133: 1328-1341.
107. McLean CA, Cherny RA, Fraser FW, Fuller SJ, Smith MJ, Beyreuther K, Bush AI, Masters CL. 1999. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46: 860-866.
108. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de CalignonA, Rozkalne A, Koenigsknecht-Talboo J, Holtzman DM, Bacskai BJ, Hyman BT. 2008. Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer's disease. Nature 451: 720-724.
109. Miller Y, Ma BY, Nussinov R. 2009. Polymorphism of Alzheimer's Aβ(17-42) (p3) oligomers: The importance of the turn location and its conformation. Biophys J 97: 1168-1177.
110. Miller Y, Ma B, Nussinov R. 2010. Zinc ions promote Alzheimer Aβ aggregation via population shift of polymorphic states. Proc Natl Acad Sci 107: 9490-9495.
111. Miyashita N, Straub JE, Thirumalai D. 2009. Structures of β-amyloid peptide 1-40, 1-42, and 1-55-the 672-726 fragment of APP-in a membrane environment with implications for interactions with gamma-secretase. J Am Chem Soc 131: 17843-17852.
112. Moore BD, Rangachari V, Tay WM, Milkovic NM, Rosenberry TL. 2009. Biophysical analyses of synthetic amyloid-β(1-42) aggregates before and after covalent cross-linking. Implications for deducing the structure of endogenous amyloid-β oligomers. Biochemistry 48: 11796-11806.
113. Mori H, Takio K, Ogawara M, Selkoe DJ. 1992. Mass spectrometry of purified amyloid β protein in Alzheimer's disease. J Biol Chem 267: 17082-17086.
114. Morinaga A, Hasegawa K, Nomura R, Ookoshi T, Ozawa D, Goto Y, Yamada M, Naiki H. 2010. Critical role of interfaces and agitation on the nucleation of Aβ amyloid fibrils at low concentrations of Aβ monomers. Biochim Biophy Acta 1804: 986-995.
115. Morita M, Vestergaard M, Hamada T, Takagi M. 2010. Real-time observation of model membrane dynamics induced by Alzheimer's amyloid beta. Biophys Chem 147: 81-86.
116. Mucke L, Selkoe D. 2011. Neurotoxicity of amyloid β-protein: Synaptic and network dysfunction. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006338.
117. Murray MM, Bernstein SL, Nyugen V, Condron MM, Teplow DB, Bowers MT. 2009a. Amyloid β protein: Aβ40 inhibits Aβ42 oligomerization. J Am Chem Soc 131: 6316-6317.
118. Murray MM, Krone MG, Bernstein SL, Baumketner A, Condron MM, Lazo ND, Teplow DB, Wyttenbach T, Shea JE, Bowers MT. 2009b. Amyloid β-protein: Experiment and theory on the 21-30 fragment. J Phys Chem B 113: 6041-6046.
119. 31P solid-state NMR. Chem Phys Lipids 158: 54-60.
120. Negureanu L, Baumketner A. 2009. Microscopic factors that control β-sheet registry in amyloid fibrils formed by fragment 11-25 of amyloid β peptide: Insights from computer simulations. J Mol Biol 389: 921-937.
121. Nerelius C, Sandegren A, Sargsyan H, Raunak R, Leijonmarck H, Chatterjee U, Fisahn A, Imarisio S, Lomas DA, Crowther DC, et al. 2009. α-Helix targeting reduces amyloid-β peptide toxicity. Proc Natl Acad Sci 106: 9191-9196.
122. Noguchi A, Matsumura S, Dezawa M, Tada M, Yanazawa M, Ito A, Akioka M, Kikuchi S, Sato M, Ideno S, et al. 2009. Isolation and characterization of patient-derived, toxic, high mass amyloid β-protein (Aβ) assembly from Alzheimer disease brains. J Biol Chem 284: 32895-32905.
123. O'Nuallain B, Freir DB, Nicoll AJ, Risse E, Ferguson N, Herron CE, Collinge J, Walsh DM. 2010. Amyloid β-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci 30: 14411-14419.
124. Ogawa M, Tsukuda M, Yamaguchi T, Ikeda K, Okada T, Yano Y, Hoshino M, Matsuzaki K. 2011. Ganglioside-mediated aggregation of amyloid β-proteins (Aβ): Comparison between Aβ-(1-42) and Aβ-(1-40). J Neurochem 116: 851-857.
125. 1-42 peptide studied using 55 MHz wireless-electrodeless quartz crystal microbalance-article no. 07GF01. Jpn J Appl Phys48doi: 10. 1143/JJAP. 48. 07GF01.
126. 2+. FEBS J276: 4051-4060.
127. Olofsson A, Sauer-Eriksson AE, Öhman A. 2009b. Amyloid fibril dynamics revealed by combined hydrogen/deuterium exchange and nuclear magnetic resonance. Anal Biochem 385: 374-376.
128. Ono K, Condron MM, Teplow DB. 2009. Structure-neurotoxicity relationships of amyloid β-protein oligomers. Proc Natl Acad Sci 106: 14745-14750.
129. Ono K, Condron MM, Teplow DB. 2010. Effects of the English (H6R) and Tottori (D7N) familial Alzheimer disease mutations on amyloid β-protein assembly and toxicity. J Biol Chem 285: 23186-23197.
130. Paparcone R, Buehler MJ. 2009. Microscale structural model of Alzheimer Aβ(1-40) amyloid fibril-article no. 243904. Appl Phys Lett 94: 43904-43904.
131. Paravastu AK, Qahwash I, Leapman RD, Meredith SC, Tycko R. 2009. Seeded growth of β-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci 106: 7443-7448.
132. Paula-Lima AC, Tricerri MA, Brito-Moreira J, Bomfim TR, Oliveira FF, Magdesian MH, Grinberg LT, Panizzutti R, Ferreira ST. 2009. Human apolipoprotein A-I binds amyloid-β and prevents A β-induced neurotoxicity. Int J Biochem Cell Biol 41: 1361-1370.
133. Perálvarez-Marín A, Mateos L, Zhang C, Singh S, Cedazo-Minguez A, Visa N, Morozova-Roche L, Graslund A, Barth A. 2009. Influence of residue 22 on the folding, aggregation profile, and toxicity of the Alzheimer's amyloid β peptide. Biophys J 97: 277-285.
134. Perreau VM, Orchard S, Adlard PA, Bellingham SA, Cappai R, Ciccotosto GD, Cowie TF, Crouch PJ, Duce JA, Evin G, et al. 2010. A domain level interaction network of amyloid precursor protein and Aβ of Alzheimer's disease. Proteomics 10: 2377-2395.
135. Perrone L, Mothes E, Vignes M, Mockel A, Figueroa C, Miquel MC, MaddeleinML, Faller P. 2009. Copper transfer from Cu-Aβ to human serum albumin inhibits aggregation, radical production and reduces Aβ toxicity. Chembiochem 11: 110-118.
136. Peters I, Igbavboa U, Schütt T, Haidari S, Hartig U, Rosello X, Bottner S, Copanaki E, Deller T, Kogel D, et al. 2009. The interaction of beta-amyloid protein with cellular membranes stimulates its own production. Biochim Biophys Acta 1788: 964-972.
137. Pham E, Crews L, Ubhi K, Hansen L, Adame A, Cartier A, Salmon D, Galasko D, Michael S, Savas JN, et al. 2010. Progressive accumulation of amyloid-β oligomers in Alzheimer's disease and in amyloid precursor protein transgenic mice is accompanied by selective alterations in synaptic scaffold proteins. FEBS J277: 3051-3067.
138. Philipson O, Hammarström P, Nilsson KPR, Portelius E, Olofsson T, IngelssonM, Hyman BT, Blennow K, Lannfelt L, Kalimo H, et al. 2009. A highly insoluble state of Aβ similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice. Neurobiol Aging 30: 1393-1405.
139. Picone P, Carrotta R, Montana G, Nobile MR, Biagio PLS, Di Carlo M. 2009. Aβ oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. Biophys J 96: 4200-4211.
140. Pitt J, Roth W, Lacor P, Smith AB, Blankenship M, Velasco P, De Felice F, BreslinP, Klein WL. 2009. Alzheimer's-associated Aβ oligomers show altered structure, immunoreactivity and synaptotoxicity with low doses of oleocanthal. Toxicol Appl Pharmacol 240: 189-197.
141. Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, Kametani F, Maeda M, Saido TC, Wang R, et al. 2005. Longer forms of amyloid β protein: Implications for the mechanism of intramembrane cleavage by γ-secretase. J Neurosci 25: 436-445.
142. Qiu L, Lewis A, Como J, Vaughn MW, Huang J, Somerharju P, Virtanen J, ChengKH. 2009. Cholesterol modulates the interaction of β-amyloid peptide with lipid bilayers. Biophys J 96: 4299-4307.
143. Rajendran R, Minqin R, Ynsa MD, Casadesus G, Smith MA, Perry G, Halliwell B, Watt F. 2009. A novel approach to the identification and quantitative elemental analysis of amyloid deposits-insights into the pathology of Alzheimer's disease. Biochem Biophys Res Commun 382: 91-95.
144. Ramos I, Fabris D, Qi W, Fernandez EJ, Good TA. 2009. Kinetic study of β-amyloid residue accessibility using reductive alkylation and mass spectrometry. Biotechnol Bioeng 104: 181-192.
145. Ravault S, Flore C, Saurel O, Milon A, Brasseur R, Lins L. 2009. Study of the specific lipid binding properties of Aβ 11-22 fragment at endosomal pH. Langmuir 25: 10948-10953.
146. Reddy G, Straub JE, Thirumalai D. 2009a. Influence of preformed Asp23-Lys28 salt bridge on the conformational fluctuations of monomers and dimers of Aβ peptides with implications for rates of fibril formation. J Phys Chem B 113: 1162-1172.
147. Reddy G, Straubb JE, Thirumalai D. 2009b. Dynamics of locking of peptides onto growing amyloid fibrils. Proc Natl Acad Sci 106: 11948-11953.
148. Reinke AA, Seh HY, Gestwicki JE. 2009. A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-β. Bioorg Med Chem Lett 19: 4952-4957.
149. Relini A, Cavalleri O, Rolandi R, Gliozzi A. 2009. The two-fold aspect of the interplay of amyloidogenic proteins with lipid membranes. Chem Phys Lipids 158: 1-9.
150. Riviere C, Delaunay JC, Immel F, Cullin C, Monti JP. 2009. The polyphenol piceid destabilizes preformed amyloid fibrils and oligomers in vitro: Hypothesis on possible molecular mechanisms. Neurochem Res 34: 1120-1128.
151. Rodríguez-Rodríguez C, Sánchez de Groot N, Rimola A, Alvarez-Larena A, Lloveras V, Vidal-Gancedo J, Ventura S, Vendrell J, Sodupe M, González-Duarte P. 2009. Design, selection, and characterization of thioflavin-based intercalation compounds with metal chelating properties for application in Alzheimer's disease. J Am Chem Soc 131: 1436-1451.
152. Roher A, Wolfe D, Palutke M, KuKuruga D. 1986. Purification, ultrastructure, and chemical analyses of Alzheimer disease amyloid plaque core protein. Proc Natl Acad Sci 83: 2662-2666.
153. Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon I, Zürcher-Neely HA, Heinrikson RL, Ball MJ, et al. 1993. Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J Biol Chem 268: 3072-3083.
154. Roher AE, Esh CL, Kokjohn TA, Castaño EM, Van Vickle GD, Kalback WM, Patton RL, Luehrs DC, Daugs ID, Kuo YM, et al. 2009. Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement 5: 18-29.
155. Ryan DA, Narrow WC, Federoff HJ, Bowers WJ. 2010. An improved method for generating consistent soluble amyloid-beta oligomer preparations for in vitro neurotoxicity studies. J Neurosci Methods 190: 171-179.
156. Rózga M, Kłoniecki M, Dadlez M, Bal W. 2010. A direct determination of the dissociation constant for the Cu(II) complex of amyloid β1-40 peptide. Chem Res Toxicol 23: 336-340.
157. Sahoo B, Nag S, Sengupta P, Maiti S. 2009. On the stability of the soluble amyloid aggregates. Biophys J 97: 1454-1460.
158. Saido T, Leissring MA. 2011. Proteolytic degradation of amyloid β-protein. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006379.
159. N3(p3), in senile plaques. Neuron 14: 457-466.
160. Sakono M, Zako T. 2010. Amyloid oligomers: Formation and toxicity of Aβ oligomers. FEBS J 277: 1348-1358.
161. Salay LC, Qi W, Keshet B, Tamm LK, Fernandez EJ. 2009. Membrane interactions of a self-assembling model peptide that mimics the self-association, structure and toxicity of Aβ(1-40). Biochim Biophys Acta 1788: 1714-1721.
162. Sanders HM, Lust R, Teller JK. 2009. Amyloid-beta peptide Aβ p3-42 affects early aggregation of full-length Aβ 1-42. Peptides 30: 849-854.
163. Sarell CJ, Syme CD, Rigby SEJ, Viles JH. 2009. Copper(II) binding to amyloid-β fibrils of Alzheimer's disease reveals a picomolar affinity: Stoichiometry and coordination geometry are independent of Aβ oligomeric form. Biochemistry 48: 4388-4402.
164. Sargaeva NP, Lin C, O'Connor PB. 2009. Identification of aspartic and isoaspartic acid residues in amyloid β peptides, including Aβ1-42, using electron-ion reactions. Anal Chem 81: 9778-9786.
165. Schauerte JA, Wong PT, Wisser KC, Ding H, Steel DG, Gafni A. 2010. Simultaneous single-molecule fluorescence and conductivity studies reveal distinct classes of Aβ species on lipid bilayers. Biochemistry 49: 3031-3039.
166. Schlenzig D, Manhart S, Cinar Y, Kleinschmidt M, Hause G, Willbold D, FunkeSA, Schilling S, Demuth HU. 2009. Pyroglutamate formation influences solubility and amyloidogenicity of amyloid peptides. Biochemistry 48: 7072-7078.
167. Schmidt M, Sachse C, Richter W, Xu C, Fändrich M, Grigorieff N. 2009. Comparison of Alzheimer Aβ(1-40) and Aβ(1-42) amyloid fibrils reveals similar protofilament structures. Proc Natl Acad Sci 106: 19813-19818.
168. Seifert F, Schulz K, Koch B, Manhart S, Demuth HU, Schilling S. 2009. Glutaminyl cyclases display significant catalytic proficiency for glutamyl substrates. Biochemistry 48: 11831-11833.
169. Selkoe DJ. 1994. Cell biology of the amyloid β-protein precursor and the mechanism of Alzheimer's disease. Ann Rev Cell Biol 10: 373-403.
170. Selkoe DJ, Abraham CR, Podlisny MB, Duffy LK. 1986. Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J Neurochem 146: 1820-1834.
171. Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. 2011. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med doi: 10. 1101/cshperspect. a006189.
172. Sevalle J, Amoyel A, Robert P, Fournié-Zaluski MC, Roques B, Checler F. 2009. Aminopeptidase A contributes to the N-terminal truncation of amyloid β-peptide. J Neurochem 109: 248-256.
173. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. 2007. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27: 2866-2875.
174. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, BrettFM, Farrell MA, Rowan MJ, Lemere CA, et al. 2008. Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 14: 837-842.
175. Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, Masliah E, Selkoe DJ, Lemere CA, Walsh DM. 2009. Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Aβ assembly forms throughout life. Neurobiol Dis 36: 293-302.
176. Simakova O, Arispe NJ. 2007. The cell-selective neurotoxicity of the Alzheimer's Aβ peptide is determined by surface phosphatidylserine and cytosolic ATP levels. Membrane binding is required for Aβ toxicity. J Neurosci 27: 13719-13729.
177. Smith DP, Ciccotosto GD, Tew DJ, Fodero-Tavoletti MT, Johanssen T, MastersCL, Barnham KJ, Cappai R. 2007. Concentration dependent Cu2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-β peptide. Biochemistry 46: 2881-2891.
178. Smith NW, Annunziata O, Dzyuba SV. 2009. Amphotericin B interactions with soluble oligomers of amyloid Aβ 1-42 peptide. Bioorg Med Chem 17: 2366-2370.
179. Söderberg L, Bogdanovic N, Axelsson B, Winblad B, Näslund J, Tjernberg LO. 2006. Analysis of single Alzheimer solid plaque cores by laser capture microscopy and nanoelectrospray/tandem mass spectrometry. Biochemistry 45: 9849-9856.
180. Song HP, Ritz S, Knoll W, Sinner EK. 2009. Conformation and topology of amyloid β-protein adsorbed on a tethered artificial membrane probed by surface plasmon field-enhanced fluorescence spectroscopy. J Struct Biol 168: 117-124.
181. Stoltenberg M, Bush AI, Bach G, Smidt K, Larsen A, Rungby J, Lund S, DoeringP, Danscher G. 2007. Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. Neuroscience 150: 357-369.
182. Streltsov VA, Varghese JN, Masters CL, Nuttall SD. 2011. Crystal structure of the amyloid-β p3 fragment provides a model for oligomer formation in Alzheimer's disease. J Neurosci 31: 1419-1426.
183. Sun X, Wu WH, Liu Q, Chen MS, Yu YP, Ma Y, Zhao YF, Li YM. 2009. Hybrid peptides attenuate cytotoxicity of β-amyloid by inhibiting its oligomerization: Implication from solvent effects. Peptides 30: 1282-1287.
184. Sureshbabu N, Kirubagaran R, Thangarajah H, Malar EJP, Jayakumar R. 2010. Lipid-induced conformational transition of amyloid β peptide fragments. J Mol Neurosci 41: 368-382.
185. Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, Funamoto S, Ihara Y. 2009. γ-Secretase: Successive tripeptide and tetrapeptide release from the transmembrane domain of β-carboxyl terminal fragment. J Neurosci 29: 13042-13052.
186. Takeda T, Klimov DK. 2009a. Probing the effect of amino-terminal truncation for Aβ(1-40) peptides. J Phys Chem B 113: 6692-6702.
187. Takeda T, Klimov DK. 2009b. Replica exchange simulations of the thermodynamics of Aβ fibril growth. Biophys J 96: 442-452.
188. Takeda T, Klimov DK. 2009c. Side chain interactions can impede amyloid fibril growth: Replica exchange simulations of Aβ peptide mutant. J Phys Chem B 113: 11848-11857.
189. Takeda T, Klimov DK. 2010. Computational backbone mutagenesis of Aβ peptides: Probing the role of backbone hydrogen bonds in aggregation. J Phys Chem B 114: 4755-4762.
190. Talmard C, Yona RL, Faller P. 2009. Mechanism of zinc(II)-promoted amyloid formation: Zinc(II) binding facilitates the transition from the partially α-helical conformer to aggregates of amyloid-β protein(1-28). J Biol Inorg Chem 14: 449-455.
191. Taniguchi A, Sohma Y, Hirayama Y, Mukai H, Kimura T, Hayashi Y, MatsuzakiK, Kiso Y. 2009. "Click peptide": pH-triggered in situ production and aggregation of monomer Aβ 1-42. Chembiochem 10: 710-715.
192. Tomic JL, Pensalfini A, Head E, Glabe CG. 2009. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis 35: 352-358.
193. Tomidokoro Y, Rostagno A, Neubert TA, Lu Y, Rebeck GW, Frangione B, Greenberg SM, Ghiso J. 2010. Iowa variant of familial Alzheimer's disease. Accumulation of posttranslationally modified Aβ D23N in parenchymal and cerebrovascular amyloid deposits. Am J Pathol 176: 1841-1854.
194. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, Ohnishi K, Ishibashi K, Teraoka R, Sakama N, Yamashita T, et al. 2010. A mouse model of amyloid β oligomers: Their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 30: 4845-4856.
195. Tõugu V, Karafin A, Zovo K, Chung RS, Howells C, West AK, Palumaa P. 2009. Zn(II)-and Cu(II)-induced non-fibrillar aggregates of amyloid-β (1-42) peptide are transformed to amyloid fibrils, both spontaneously and under the influence of metal chelators. J Neurochem 110: 1784-1795.
196. Tycko R, Sciarretta KL, Orgel J, Meredith SC. 2009. Evidence for novel β-sheet structures in Iowa mutant β-amyloid fibrils. Biochemistry 48: 6072-6084.
197. Uranga RM, Giusto NM, Salvador GA. 2010. Effect of transition metals in synaptic damage induced by amyloid beta peptide. Neuroscience 170: 381-389.
198. Urbanc B, Betnel M, Cruz L, Bitan G, Teplow DB. 2010. Elucidation of amyloid β-protein oligomerization mechanisms: Discrete molecular dynamics study. J Am Chem Soc 132: 4266-4280.
199. Utsumi M, Yamaguchi Y, Sasakawa H, Yamamoto N, Yanagisawa K, Kato K. 2009. Up-and-down topological mode of amyloid β-peptide lying on hydrophilic/hydrophobic interface of ganglioside clusters. Glycoconj J 26: 999-1006.
200. Villemagne VL, Perez KA, Pike KE, Kok WM, Rowe CC, White AR, Bourgeat P, Salvado O, Bedo J, Hutton CA, et al. 2010. Blood-borne amyloid-β dimer correlates with clinical markers of Alzheimer's disease. J Neurosci 30: 6315-6322.
201. Walsh DM, Selkoe DJ. 2007. Aβ oligomers-a decade of discovery. J Neurochem 101: 1172-1184.
202. Walsh DM, Lomakin A, Benedek GB, Maggio JE, Condron MM, Teplow DB. 1997. Amyloid β-protein fibrillogenesis: Detection of a protofibrillar intermediate. J Biol Chem 272: 22364-22374.
203. Walsh DM, Thulin E, Minogue AM, Gustavsson N, Pang E, Teplow DB, Linse S. 2009. A facile method for expression and purification of the Alzheimer's disease-associated amyloid β-peptide. FEBS J 276: 1266-1281.
204. Wang QM, Zhao C, Zhao J, Wang JD, Yang JC, Yu X, Zhen J. 2010. Comparative molecular dynamics study of Aβ adsorption on the self-assembled monolayers. Langmuir 26: 3308-3316.
205. Wei GH, Jewett AI, Shea JE. 2010. Structural diversity of dimers of the Alzheimer amyloid-β(25-35) peptide and polymorphism of the resulting fibrils. Phys Chem Chem Phys 12: 3622-3629.
206. Weidemann A, Eggert S, Reinhard FB, Vogel M, Paliga K, Baier G, Masters CL, Beyreuther K, Evin G. 2002. A novel ε-cleavage within the transmembrane domain of the Alzheimer amyloid precursor protein demonstrates homology with Notch processing. Biochemistry 41: 2825-2835.
207. Welander H, Frånberg J, Graff C, Sundström E, Winblad B, Tjernberg LO. 2009. Aβ 43 is more frequent than Aβ 40 in amyloid plaque cores from Alzheimer disease brains. J Neurochem 110: 697-706.
208. Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, et al. 2010. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J Neural Transm 117: 85-96.
209. Woltjer RL, Sonnen JA, Sokal I, Rung LG, Yang W, Kjerulf JD, Klingert D, Johnson C, Rhew I, Tsuang D, et al. 2009. Quantitation and mapping of cerebral detergent-insoluble proteins in the elderly. Brain Pathol 19: 365-374.
210. Wu C, Murray MM, Bernstein SL, Condron MM, Bitan G, Shea JE, Bowers MT. 2009. The structure of Aβ 42 C-terminal fragments probed by a combined experimental and theoretical study. J Mol Biol 387: 492-501.
211. 9-40 peptide: A comparison to agitated fibrils. PLoS Comput Biol 6: e1000693. doi: 10. 1372/journal/pcbi. 1000693.
212. Wu JW, Breydo L, Isas JM, Lee J, Kuznetsov YG, Langen R, Glabe C. 2010b. Fibrillar oligomers nucleate the oligomerization of monomeric amyloid β but do not seed fibril formation. J Biol Chem 285: 6071-6079.
213. Xia WM, Yang T, Shankar G, Smith IM, Shen Y, Walsh DM, Selkoe DJ. 2009. A specific enzyme-linked immunosorbent assay for measuring β-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch Neurol 66: 190-199.
214. Xiao Z, Wedd AG. 2010. The challenges of determining metal-protein affinities. Nat Prod Rep 27: 768-789.
215. Yadav A, Sonker M. 2009. Perspectives in designing anti-aggregation agents as Alzheimer disease drugs. Euro J Med Chem 44: 3866-3873.
216. Yagi-Utsumi M, Kameda T, Yamaguchi Y, Kato K. 2010. NMR characterization of the interactions between lyso-GM1 aqueous micelles and amyloid-β. FEBS Lett 584: 831-836.
217. Yamin G, Ruchala P, Teplow DB. 2009. A peptide hairpin inhibitor of amyloid β-protein oligomerization and fibrillogenesis. Biochemistry 48: 11329-11331.
218. Yang C, Li JY, Li Y, Zhu XL. 2009a. The effect of solvents on the conformations of Amyloid β-peptide (1-42) studied by molecular dynamics simulation. J Mol Struct: THEOCHEM 895: 1-8.
219. Yang C, Zhu XL, Li JY, Chen K. 2009b. Molecular dynamics simulation study on conformational behavior of Aβ(1-40) and Aβ(1-42) in water and methanol. J Mol Struct: THEOCHEM 907: 51-56.
220. Yu LP, Edalji R, Harlan JE, Holzman TF, Lopez AP, Labkovsky B, Hillen H, Barghorn S, Ebert U, Richardson PL, et al. 2009. Structural characterization of a soluble amyloid β-peptide oligomer. Biochemistry 48: 1870-1877.
221. Zhang A, Qi W, Good TA, Fernandez EJ. 2009a. Structural differences between Aβ(1-40) intermediate oligomers and fibrils elucidated by proteolytic fragmentation and hydrogen/deuterium exchange. Biophys J 96: 1091-1104.
222. A receptor-mediated currents in rat hippocampal CA1 neurons. Prog Natl Sci 19: 963-972.
223. Zhang L, Yu HX, Song CC, Lin XF, Chen B, Tan C, Cao GX, Wang ZW. 2009c. Expression, purification, and characterization of recombinant human β-amyloid42 peptide in Escherichia coli. Protein Expres Purif 64: 55-62.
224. 1-42 peptides in amyloid fibrils revealed by cryoEM. Proc Natl Acad Sci 106: 4653-4658.
225. Zhao JH, Liu HL, Liu YF, Lin HY, Fang HW, Ho Y, Tsai WB. 2009. Molecular dynamics simulations to investigate the aggregation behaviors of the Aβ(17-42) oligomers. J Biomol Struct Dyn 26: 481-490.
226. Zheng J, Yu X, Wang J, Yang JC, Wang Q. 2010. Molecular modeling of two distinct triangular oligomers in amyloid β-protein. J Phys Chem B 114: 463-470.